Allison Hoffman Sells 6,176 Shares of Phreesia (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) General Counsel Allison Hoffman sold 6,176 shares of the business’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $11.97, for a total value of $73,926.72. Following the completion of the transaction, the general counsel directly owned 163,485 shares of the company’s stock, valued at approximately $1,956,915.45. This trade represents a 3.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Phreesia Stock Up 3.1%

Shares of PHR opened at $11.64 on Friday. The company has a market capitalization of $701.44 million, a price-to-earnings ratio of -116.34 and a beta of 0.67. Phreesia, Inc. has a 52 week low of $10.75 and a 52 week high of $32.76. The stock’s 50-day moving average price is $12.72 and its 200-day moving average price is $18.00. The company has a quick ratio of 2.44, a current ratio of 2.44 and a debt-to-equity ratio of 0.01.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in PHR. Loomis Sayles & Co. L P purchased a new position in shares of Phreesia during the 2nd quarter valued at approximately $34,162,000. Granahan Investment Management LLC raised its position in Phreesia by 73.8% during the fourth quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company’s stock worth $40,601,000 after acquiring an additional 1,018,987 shares during the period. Prosight Management LP acquired a new position in Phreesia during the fourth quarter worth $16,533,000. Millennium Management LLC lifted its holdings in Phreesia by 730.7% during the third quarter. Millennium Management LLC now owns 1,064,132 shares of the company’s stock valued at $25,028,000 after purchasing an additional 936,033 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new position in Phreesia during the fourth quarter valued at $15,213,000. 92.10% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on PHR shares. Citigroup dropped their price objective on shares of Phreesia from $29.00 to $25.00 and set a “buy” rating on the stock in a research note on Friday, January 9th. Canaccord Genuity Group decreased their target price on shares of Phreesia from $38.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, December 9th. Wall Street Zen lowered shares of Phreesia from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 8th. Mizuho cut their price objective on shares of Phreesia from $22.00 to $19.00 and set an “outperform” rating for the company in a report on Tuesday. Finally, Zacks Research downgraded shares of Phreesia from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. Seventeen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $28.65.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.